David R. Greeley shares Phase II results of AR1001, a potential Alzheimer’s treatment 🧠

Patients showed significant reductions in p-tau181, especially those w/ mild disease. Phase III will focus on earlier stages of AD: ow.ly/fH5c50PEg3a

AD/PD - Advances in Science & Therapy

The European Task Force for Brain Health Services advocates for risk detection & stratification in dementia

Giovanni Frisoni (@unige_en) highlights the need to shift to early prevention in memory clinics: vjdementia.com/video/ck8_xxh8…

#ADPD23 AD/PD - Advances in Science & Therapy

Detecting retinal Aβ: a promising path for non-invasive #Alzheimers diagnosis

Mourad Tayebi (Western Sydney University) discusses his work towards the development of an ‘eye test’ for AD using nanobodies targeted to retinal Aβ oligomers: ow.ly/bgBx50PsUkL

#Dementia #NeuroTwitter

Philip Tipton (Mayo Clinic) discusses the use of focused ultrasound in #Alzheimers

FUS could be used with anti-amyloid therapies to deliver higher concentrations than previously achieved & has been shown to improve MMSE scores: ow.ly/P06Z50PsUeG

#Neurology #NeuroTwitter

Arshia Khan (UMN Duluth) & her team have been developing humanoid robots to improve the quality of care in nursing homes

Prof. Khan shares the key capabilities of the robots, which address physical, emotional & cognitive well-being: ow.ly/WUct50PsU4o

#AAIC23 #NeuroTwitter

📊A review of current clinical trials in #dementia with Lewy bodies

Carla Abdelnour talks on key takeaways
-Limited participant diversity
-Mostly repurposed agents
-Use of outcome measures not validated in DLB

Find out more: ow.ly/yZEv50PsTSB

#AAIC23 #NeuroTwitter

Katerina Akassoglou (UC San Francisco) uncovers how cerebrovascular damage links to immune-mediated degeneration

💡Fibrinogen key in the induction of pathogenic neuroinflammation, activating neurodegenerative signatures in microglia: ow.ly/nrxc50PsSWu

#Alzheimers #AAIC23

Christina Jensen-Dahm (Danish Dementia Research Centre) investigated the consequences of opioid use in people with #dementia , revealing a 4-fold excess mortality risk, 11-fold in the initial weeks

Learn more: ow.ly/Eebh50PsSwo

#AAIC23 Alzheimer's Association #Neurology #NeuroTwitter #Alzheimers

📢 #AAIC23 presents a game-changer!

Hanna Huber & Nicholas Ashton (Uni of Gothenburg) present DROP-AD pilot study—a simple finger prick method for #Alzheimers biomarker detection. Strong correlation with venous samples.

▶️ow.ly/Pxt350PsRQW

Alzheimer's Association #NeuroTwitter

Suzanne Schindler (Washington U. Med) shares her work looking into the accuracy of blood-based biomarkers in #Alzheimers .

A test analyzing the ratio of phospho to non-phospho tau217 exhibits exceptional accuracy in predicting amyloid-PET: ow.ly/PxJW50PsRHP

#AAIC23 Alzheimer's Association

Xin Xu (Zhejiang University) shares results of a voice-recognition-based cognitive screener for MCI & dementia in Chinese seniors

Achieved 97.5% completion rate in 5.6-6.1 mins. Predictive validity near 90%.

Check it out: ow.ly/vgzQ50PsR6a

Alzheimer's Association #Neurology #NeuroTwitter

📢 #AAIC23 : Alina Solomon (University of Eastern Finland) explores the impact of genetic risk scores on the value of multidomain #dementia prevention.

Preliminary results indicate greater benefits in higher risk patients, especially APOE4 carriers: ow.ly/iOVJ50PsQLX

#NeuroTwitter

The PMN310 mAb is selective for soluble toxic Aβ oligomers & does not bind to monomers and plaques

Johanne Kaplan (ProMIS Neurosciences) explains the importance of selectivity of Aβ-directed antibodies in #Alzheimers disease: ow.ly/jjcY50P5lqh

#Dementia #Neurology #NeuroTwitter

Santiago Solé-Domènech & Rudy Gregory Jacquet of Weill Cornell Medicine share their thoughts on the potential of lysosomal function enhancement as a therapeutic strategy in #Alzheimers disease
👉ow.ly/u3up50P5lgy

AD/PD - Advances in Science & Therapy #ADPD2023 #Dementia #Neurology #NeuroTwitter

🆕🧬➡️ All-in-one AAV-delivered dCas9-based repressor for APOE silencing

Boris Kantor (Duke University School of Medicine) shares new developments from his research into APOE-targeted epigenome editing technology for #Alzheimers disease: ow.ly/Zo9i50P5lbe

#Dementia #Neurology #NeuroTwitter

Tacrolimus for #dementia prevention?

Jacqueline Silva (UTMB Health) explains the significance of calcineurin inhibitors (CNIs) in reducing the prevalence of dementia: ow.ly/vJVm50P5l73

AD/PD - Advances in Science & Therapy #ADPD2023 #Dementia #Neurology #NeuroTwitter

#WorldBrainDay | Neurological disorders, inc. neurodegenerative disorders, are a leading cause of brain disability.

Suzanne Hendrix talks about how we can use ‘time saved’ as a measure of clinical meaningfulness for DMT trials: ow.ly/urzX50PiOob

Search #WBD2023 for more!

#WorldBrainDay is on the 22nd July!

Awareness, prevention, advocacy, education and access are the key messages of #WBD2023

Visit wfneurology.org/world-brain-da… to learn more about #WBD2023 and follow us VJDementia for updates in research about brain health and disability.

It's #WorldBrainDay & VJDementia are getting involved!

“This is our chance to show up for people with disabilities that stem from neurological diseases and create a global effort to break down barriers that prevent them from achieving the highest possible standard of health…

#AAIC23 attendees: SAVE THE DATE for #AAIC24 , July 28-August 1, 2024 in Philadelphia, PA, USA and online. We'll see you next year!